Carbon Ion RT for Locally Advanced Pancreatic Cancer
NCT04592861 is a phase 3 interventional trial sponsored by Albert Einstein College of Medicine. As of 21 Nov 2026, it was terminated. It studies Chemotherapy drug in Pancreatic Cancer. The registry lists an enrollment of 5 participants at 1 site in 1 country. The registry lists a start date of 1 Nov 2020 and a primary completion date of 24 Aug 2022. One of its registered investigators has a FindMyKOL profile.
Key facts
Registry attributes as recorded on the ClinicalTrials.gov study record.
| Field | Value |
|---|---|
| Registry ID | NCT04592861 |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional trial |
| Lead sponsor | Albert Einstein College of Medicine |
| Enrollment | 5 |
| Registered sites | 1 |
| Countries | 1 |
| Conditions | Pancreatic Cancer |
| Drugs | Chemotherapy drug |
| Start | 1 Nov 2020 |
| Primary completion | 24 Aug 2022 |
| Study completion | 24 Aug 2022 |
| Last update posted | 5 Jan 2024 |
Registered summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Shanghai Proton and Heavy Ion Center (sphic)
Shanghai, Shanghai Municipality
Sites by country
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Questions about NCT04592861
Each answer restates registry values shown on this page.
What is NCT04592861?
NCT04592861 is a phase 3 interventional trial sponsored by Albert Einstein College of Medicine. It studies Chemotherapy drug in Pancreatic Cancer.
Who leads NCT04592861?
The registry names Nitin Ohri, MD (principal investigator, Associate Professor) as the overall official.
Where does NCT04592861 run?
The registry lists 1 site in 1 country. Every site with a stated country is in one country: China.
Which drugs does NCT04592861 study?
The registered drug and biological interventions are Chemotherapy drug.
When did NCT04592861 end?
The registry lists a primary completion date of 24 Aug 2022 and a study completion date of 24 Aug 2022. The sponsor last updated the record on 5 Jan 2024.
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.